Discovering breakthroughs in fibrosis and neurodegeneration

Our Mission

To bring life-changing treatments to patients with fibrotic and neurodegenerative diseases

Blade Therapeutics is a biopharmaceutical company focused on developing cutting-edge treatments for fibrotic and neurodegenerative diseases that impact millions of people worldwide. We are a leader in novel biological pathways – including autotaxin / LPA and calpain biology – that are foundational to cell- and tissue-damage responses resulting from protein deposition or aggregation associated with fibrotic and neurodegenerative diseases. 

Our focused approach offers the potential to produce disease-modifying, life-saving therapies. Since our founding in 2015, the Company has assembled critical leadership expertise supplemented by a world-class network of scientific, pharmaceutical and clinical advisors to enable efficient and successful drug development.

Blade is advancing a differentiated pipeline of oral, small-molecule therapies that include a non-competitive autotaxin inhibitor and inhibitors of dimeric calpains designed for the potential treatment of lung, liver and cardiac fibrosis or neurodegenerative diseases.

Our Leadership

Management Team

Wendye Robbins photo

Wendye Robbins, M.D.

President & CEO

Jean Viret photo

Jean-Frédéric Viret, Ph.D.

Chief Financial Officer

Prabha Ibrahim photo

Prabha Ibrahim, Ph.D.

Chief Technology Officer

Felix Karim photo

Felix Karim, Ph.D.

Executive Vice President, Business Development

photo of Bassem Elmankabadi, M.D.

Bassem Elmankabadi, M.D.

Senior Vice President of Clinical Development

photo of Daven Mody

Daven Mody, PharmD. MBA

Senior Vice President, Global Regulatory Affairs, Quality, and Safety

photo of Ravi Rajagopalan

Ravi Rajagopalan, Ph.D.

Vice President, Biology, Drug Discovery & Development

Michael Blash photo

Michael Blash

Senior Vice President, Communications

Krishna Gorti photo

Krishna Gorti, M.D., FRCS

Investor Relations

Board Of Directors

Mark Timney photo

Mark Timney

Chairman Of The Board For Blade

Luke Evnin photo

Luke Evnin, Ph.D.

Co-Founder and Managing Director at MPM Capital

Cameron Wheeler photo

Cameron Wheeler, Ph.D.

Partner at Deerfield

William Slattery photo

William Slattery

Partner at Deerfield

Rana Al-Hallaq photo

Rana Al-Hallaq, Ph.D.

Senior Director And Principal at Pfizer Ventures

photo of Lloyd Klickstein

Lloyd Klickstein, M.D., Ph.D.


Wendye Robbins photo

Wendye Robbins, M.D.

President & CEO
Blade Therapeutics, Inc.

Scientific Advisors

Hal Dietz Photo

Hal Dietz, M.D.

Blade’s Founder

Oliver Eickelberg Photo

Oliver Eickelberg, M.D.

Scientific Advisor

Scott Friedman Photo

Scott Friedman, M.D.

Scientific Advisor

peter hirth Photo

Peter Hirth, Ph.D.

Scientific Advisor

Richard Hynes Photo

Richard Hynes, Ph.D.

Scientific Advisor

Mervyn Turner Photo

Mervyn Turner

Scientific Advisor

In Memoriam

Alan Mendelson photo

Alan C. Mendelson

General Counsel & Secretary

John Nicholas image

John Nicholas, Ph.D

Vice President, Data Science

andrew tager image

Andrew Tager, M.D.

Scientific Advisor


mpm logo

deerfield logo

Osage University Partners logo

bristol myers squibb logo

novartis logo

pfizer ventures logo

One Ventures logo

Bay City Capital logo


Blade is actively seeking to in-license clinical or preclinical assets to expand our pipeline.

We are seeking to evaluate opportunities that represent a wide variety of molecular targets.

Parties developing products or technologies for fibrotic or neurodegenerative diseases that are interested in collaborating with Blade should contact our business development team. Contact:

Blade has partnered with the Scleroderma Research Foundation (SRF) to treat disorders of fibrosis, including scleroderma. Our founder, Hal Dietz, M.D., has been working closely with SRF for several years, and Blade has provided support through its research grant program.